LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Search

Penumbra Inc

Closed

SectorHealthcare

320.7 0.4

Overview

Share price change

24h

Current

Min

319.37

Max

321.56

Key metrics

By Trading Economics

Income

163M

33M

Sales

-11M

375M

P/E

Sector Avg

73.491

49.888

EPS

0.82

Profit margin

8.695

Employees

4,700

EBITDA

-30M

38M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+12.17% upside

Dividends

By Dow Jones

Next Earnings

28 Jul 2026

Market Stats

By TradingEconomics

Market Cap

-224M

13B

Previous open

320.3

Previous close

320.7

News Sentiment

By Acuity

50%

50%

154 / 344 Healthcare

Penumbra Inc Chart

Past performance is not a reliable indicator of future results.

Related News

15 Jan 2026, 13:29 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15 Jan 2026, 12:35 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15 Jan 2026, 12:29 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

6 May 2026, 20:15 UTC

Earnings

Penumbra Not Be Providing Fincl Guidance Due to Pending Acquisition by Boston Scientific >PEN

6 May 2026, 20:07 UTC

Earnings

Penumbra 1Q Rev $374.8M >PEN

6 May 2026, 20:07 UTC

Earnings

Penumbra 1Q EPS 82c >PEN

25 Feb 2026, 18:02 UTC

Earnings

Penumbra: Won't Be Providing Financial Guidance for 2026, Citing Proposed Boston Scientific Deal

25 Feb 2026, 18:01 UTC

Earnings

Penumbra 4Q Rev $385.4M >PEN

25 Feb 2026, 18:01 UTC

Earnings

Penumbra 4Q Adj EPS $1.18 >PEN

25 Feb 2026, 18:01 UTC

Earnings

Penumbra 4Q EPS $1.20 >PEN

24 Jan 2026, 06:18 UTC

Acquisitions, Mergers, Takeovers

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

15 Jan 2026, 14:37 UTC

Hot Stocks

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15 Jan 2026, 13:45 UTC

Acquisitions, Mergers, Takeovers

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15 Jan 2026, 12:04 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15 Jan 2026, 12:03 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15 Jan 2026, 12:01 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15 Jan 2026, 12:00 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15 Jan 2026, 12:00 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

Peer Comparison

Price change

Penumbra Inc Forecast

Price Target

By TipRanks

12.17% upside

12 Months Forecast

Average 358.25 USD  12.17%

High 374 USD

Low 335 USD

Based on 4 Wall Street analysts offering 12 month price targets forPenumbra Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

1

Buy

3

Hold

0

Sell

Sentiment

By Acuity

154 / 344 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat